Mar 06, 2023 / 07:10PM GMT
Charles R. Kummeth - Bio-Techne Corporation - CEO, President & Director
Thanks, Bio-Techne, and glad you all came. It's been a while since we've been standing-room only. Thank you. Safe harbor, of course, I think you guys all know what that is. We always need time. All right, Bio-Techne. So I've been here about 10 years at the helm. At this point, we're roughly between $12 billion and $13 billion market cap. We are largely a life science tools company, we're getting into diagnostics as well. It's very related to assays, which we -- we know a lot about. You can see we're 81% consumables, 11% instruments, but a full 10% is consumables for the instruments. So the cartridges that make them work. So we're roughly really a 20% instrument-based company as well.
We have these 8 more or less platforms here that we have our businesses arranged under by technology, proteins that are most known for. We're the world leader in proteins for research. We're one of the top players in antibodies. There's only 100 of us out there. We're pretty big compared to most. Immunoassay's, we are the inventor and creator
Bio-Techne Corp at Cowen Health Care Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot